CSBio CSBio

X
[{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Reaches Agreement on a Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Phebra"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Advances Cell Line Development for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures New European Patent for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Selects Charles River Laboratories for IMP761\u2019s GLP Toxicology Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.

            Lead Product(s): Arsenic Trioxide

            Therapeutic Area: Immunology Product Name: ArsciCor

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BioSenic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 15, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Charles River will conduct a GLP toxicology study for IMP761, a first-in-class LAG-3 agonist antibody and Immutep's proprietary preclinical candidate for autoimmune diseases.

            Lead Product(s): IMP761

            Therapeutic Area: Immunology Product Name: IMP761

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Charles River Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IMP761 is first-in-class immunosuppressive agonist antibody to LAG-3 has potential to address root cause of AID by specifically silencing autoimmune memory T cells that accumulate at disease site and express LAG-3.

            Lead Product(s): IMP761

            Therapeutic Area: Immunology Product Name: IMP761

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases.

            Lead Product(s): IMP761

            Therapeutic Area: Immunology Product Name: IMP761

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Using its STEP®-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761.

            Lead Product(s): IMP761

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY